Last reviewed · How we verify

Institut Investigacio Sanitaria Pere Virgili — Portfolio Competitive Intelligence Brief

Institut Investigacio Sanitaria Pere Virgili pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Niacin plus laropiprant Niacin plus laropiprant marketed Lipid-modifying agent combination DP1 receptor (laropiprant component); niacin acts on GPR109A and other pathways Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Merck Sharp & Dohme LLC · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Institut Investigacio Sanitaria Pere Virgili:

Cite this brief

Drug Landscape (2026). Institut Investigacio Sanitaria Pere Virgili — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/institut-investigacio-sanitaria-pere-virgili. Accessed 2026-05-17.

Related